What is new in the etiopathogenesis and treatment of dermatitis seborrhoica;Co nowego w etiopatogenezie i leczeniu łojotokowego zapalenia skóry

Postepy Dermatologii I Alergologii

Volumn 22, Issue 1, 2005, Pages 10-13

  Brzezińska Wcisło, Ligia ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Clinical symptoms; Etiopatogenesis; Management; Seborrhoeic dermatitis

Indexed keywords

CALCIPOTRIOL; CORTICOSTEROID; ERYTHROMYCIN; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; METRONIDAZOLE; PIMECROLIMUS; TACROLIMUS;

ARTICLE; CLINICAL FEATURE; CLINICAL PROTOCOL; DIAGNOSTIC VALUE; DISEASE RESISTANCE; HUMAN; PATHOGENESIS; SCALP; SEBACEOUS GLAND; SEBORRHEIC DERMATITIS; SYMPTOMATOLOGY;

EID: 14844349557     PISSN: 1642395X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Rebora A, Rongioletti F: The red face. Seborrhoeic dermatitis. Clin Dermatol 1993, 11: 243-51.
2. Braun-Falco O, Plewig G, Wolff H, et al.: Łojotokowe zapalenie skóry W: Dermatologia, Czelej Lublin, 2002: 462-6.
3. Kozłowska A: Łojotokowe zapalenie skóry. Etiologia i leczenie. Medipress Dermatol 1990, 1: 3-8.
4. Jabłońska S: Schorzenia łojotokowe. W: Choroby skóry. S Jabłońska (red). PZWL Warszawa, 1980: 943-8.
5. Ippolito F, Passi S, Di-Carlo A: Is seborrhoeic dermatitis a clinical marker of HIV disease? Minerva Ginecol 2000, 52: 54-8.
6. Czyz P, Ryglewska-Cho A, Miekoś-Zydek B i wsp.: Nowe poglady na etiopatogenze i leczenie łojotokowego zapalenia skóry. Nowa Klinika 2003, 10: 1104-6.
7. Mayser P, Gross A: IgE antibodies of Malassezia furfur. M. sympodialis and Pityrosporum orbiculare in patients with atopic dermatitis seborrhoeic eczema or pityriasis versicolor and identification of respective allergens. Acta Derm Venereol 2000, 80: 357-61.
8. Parry ME, Skarpe GR: Seborrhoeic dermatitis is not caused by an altered immune response to Malassezia yeasts. Br J Dermatol 1998, 139: 254-63.
9. Gupta AK, Kohli Y, Summerbell RC, et al.: Quantitative culture of Malassezia species from different body sites of individuals with of without dermatoses. Med Mycol 2001, 39: 243-51.
10. Kim SC, Kim HU: The distribution of Malassezia species on the normal human skin according to body region. Korean J Med Mycol 2000, 5: 120-8.
11. Faergemann J: Management of seborrheis dermatitis and pityriasis versicolor. Am J Clin Dermatol 2000, 1: 75-80.
12. Faergemann J: Bergbrant M, Dohse M, et al.: Seborrhoeic dermatitis and Pityrosporum (Malassezia) folliculitis: Charakterization of inflammatory cells and mediators in the skin by immunohistochemistry Br J Dermatol 2001, 144: 549-56.
13. Neuber K, Kroger S, Gruseck E, et al.: Effecs of Pityrosporum ovale on proliferation, immunoglobulin (IgA, G, M) synthesis and cytokine (IL-2; IL-10, IFN-γ) production of peripheral blood mononuclear cells from patients with seborrhoeic dermatitis. Arch Dermatol 1996, 288: 532-6.
14. Gupta A, Madzia S, Batra R: Etiology and management of Seborrhoeic dermatitis, Dermatology 2004, 208: 85-93.
15. Hay RJ, Graham-Brown RA: Dandruff and Seborrhoeic dermatitis: Causes and management. Clin Exp Dermatol 1997, 22: 3-6.
16. Baroni A, Perfetto B, Paoletti I, et al.: Malassezia furfur invasiveness in a keratinocyte cell line (HaCat): Effects on cytoskeleton and on adhesion molecule and cytokine expression. Arch Dermatol 2001, 293: 414-9.
17. Watanabe S, Kano R, Sato H, et al.: The effects of Malassezia yeasts on cytokine production by human keratinocytes. J Invest Dermatol 2001, 116: 769-73.
18. Bergbrant JM: Seborrhoeic dermatitis and Pityrosporum ovale: cultural, immunologic and clinical studies. Acta Derm Venereol 1991, suppl 167: 1-36.
19. Broberg A: Pityrosporum ovale in healthy children, infantile seborrhoeic dermatitis and atopic dermatitis. Acta Derm Venereol 1994, suppl 191: 1-47.
20. Miklaszewska M, Wasik F: Dermatologia pediatryczna. Volumed Wrocław, 1999, 112.
21. Tollesson A, Essential fatty acides in infantile seborrhoeic dermatitis J Am Acad Dermatol 1993, 28: 957-61.
22. Zouboulis CC: Retinoids - which dermatological indications will benefit in the near future? Skin Pharmacol Appl Skin Physiol 2001, 14: 303-15.
23. Pirkhammer D, Seeber A, Honigsmann H, et al.: Narrow - band ultravioler B (TL-01) phototherapy is an effective and safe treatment option for patients with severe seborrhoeic dermatitis. Br J Dermatol 2000, 43: 946-68.
24. Johnson BA, Nuhley JR: Treatment of seborrhoeic dermatitis. Am Fam Phys 2000, 61: 2703-14.
25. Ghannoum MA, Kuhn DM. Voriconazole - better chances for patients with invasive mycoses. Eur J Med Res 2002, 7: 242-56.
26. Gupta AK, Einarson TR, Summerbell RC, et al.: An overview of topical antifungal therapy in dermatomycoses. A North American perspective. Drugs 1998, 55: 645-74.
27. Elewski BE: Mechanisms of action of systemic antifungal agents. J Am Acad Dermatol 1993, 28: 28-34.
28. Schemer A, Nathansohn N, Kaplan B, et al.: Treatment of scalp seborrheic dermatitis and psoriasis with an ointment of 40% urea and 1% bifonazole. Int J Dermatol 2000, 39: 532-4.
29. Caputo R, Barbareschi M: Itraconazole: New horizons G. Ital Dermatol Venereol 2002, 137: 1-7.
30. Rosen T, Schell BJ, Orengo J: Anti-inflammatory acticity of antifungal preparations. Int J Dermatol 1997, 36: 788-92.
31. McGrath J, Murphy GM: The control of seborrhoeic dermatitis and dandruff by antipityrosporal drugs. Drugs 1991, 41: 178-84.
32. Basak PY, Ergin S: Comparative effects of calcipotriol and betamethasone 17-valerate solution in the treatment of seborrhoeic dermatitis of the scalp. J Eur Acad Dermatol Venereol 2001, 15: 86-8.
33. Braza TJ, Dicarlo JB, Soon SL, et al.: Tacrolimus 0,1% ointment for seborrhoeic dermatitis: an open label study. Br J Dermatol 2003, 148: 1242-4.
34. Crutchfield CE III: Pimecrolimus: A new treatment of seborrhoeic dermatitis. Cutis 2002, 70: 207-8.
35. Nakagawa H, Etoh T, Yokota Y, et al.: Tacrolimus has antifungal activities against Malassezia furfur isolated from healthy adults and patients with atopic dermatitis. Clin Drug Invest 1996, 12: 245-50.